中药注射剂对脓毒症患者28天死亡率的影响:EXIT-SEP随机临床试验
EXIT-SEP是一项在45个ICU中心开展的多中心、随机双盲、安慰剂对照试验,纳入1817例病程<48小时的脓毒症(sepsis 3.0)患者,年龄18-75岁、SOFA评分2-13分,随机接受血必净注射液100 mL或等容量生理盐水安慰剂静脉输注,每12小时一次、持续5天。主要终点28天死亡率:安慰剂组26.1%(230/882)vs 血必净组18.8%(165/878),P<.001,绝对风险差7.3个百分点(95%CI 3.4-11.2)。不良事件发生率安慰剂组25.3%(222/878)vs 血必净组22.9%(200/872)。作者结论认为,在脓毒症患者中血必净注射液较安慰剂降低28天死亡率。
要点
- 28天死亡率:安慰剂组26.1%(230/882)vs 血必净组18.8%(165/878),P<.001,绝对风险差7.3个百分点(95%CI 3.4-11.2)。
- 给药方案:血必净注射液100 mL静脉输注,每12小时一次、持续5天;对照组为等容量生理盐水安慰剂。
- 纳入标准:脓毒症(sepsis 3.0)病程<48小时、年龄18-75岁、SOFA评分2-13分;共1817例随机。
- 不良事件:安慰剂组25.3%(222/878)vs 血必净组22.9%(200/872)。
- 1760例(96.9%)完成试验;研究于2017年10月至2019年6月进行,末次随访2019年7月26日。
适用人群与场景
- ICU内脓毒症(sepsis 3.0)患者,病程<48小时,年龄18-75岁,SOFA评分2-13分。
- 共1817例随机(平均[SD]年龄56.5[13.5]岁;男性1199例[66.0%]),来自45个中心的ICU。
诊断标准与关键阈值
- 脓毒症诊断依据sepsis 3.0标准,病程<48小时。
- SOFA评分2-13分。
- 年龄18-75岁。
处置流程与药物剂量
- 血必净注射液100 mL静脉输注,每12小时一次,持续5天。
- 对照组给予等容量生理盐水安慰剂,每12小时一次,持续5天。
研究设计与关键结果
- 研究类型:多中心、随机双盲、安慰剂对照试验(EXIT-SEP),45个中心,1817例随机,1760例(96.9%)完成试验。
- 主要终点28天死亡率:安慰剂组26.1%(230/882)vs 血必净组18.8%(165/878),P<.001;绝对风险差7.3个百分点(95%CI 3.4-11.2)。
- 不良事件发生率:安慰剂组25.3%(222/878)vs 血必净组22.9%(200/872)。
- 研究时间:2017年10月至2019年6月;末次随访2019年7月26日;数据分析2020年1月至2022年8月。
证据类型、等级与局限
- 证据类型:多中心、随机双盲、安慰剂对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在脓毒症患者中给予血必净注射液较安慰剂降低28天死亡率。
- 适用人群为ICU内脓毒症(sepsis 3.0)病程<48小时、年龄18-75岁、SOFA评分2-13分的患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Previous research has suggested that Xuebijing injection (XBJ), an herbal-based intravenous preparation, may reduce mortality among patients with sepsis.
OBJECTIVE: To determine the effect of XBJ vs placebo on 28-day mortality among patients with sepsis.
DESIGN, SETTING, AND PARTICIPANTS: The Efficacy of Xuebijing Injection in Patients With Sepsis (EXIT-SEP) trial was a multicenter, randomized double-blind, placebo-controlled trial conducted in intensive care units at 45 sites and included 1817 randomized patients with sepsis (sepsis 3.0) present for less than 48 hours. Patients aged 18 to 75 years with a Sequential Organ Failure Assessment score of 2 to 13 were enrolled. The study was conducted from October 2017 to June 2019. The final date of follow-up was July 26, 2019. Data analysis was performed from January 2020 to August 2022.
INTERVENTIONS: The patients were randomized to receive either intravenous infusion of XBJ (100 mL, n = 911) or volume-matched saline placebo (n = 906) every 12 hours for 5 days.
MAIN OUTCOMES AND MEASURES: The primary outcome was 28-day mortality.
RESULTS: Among the 1817 patients who were randomized (mean [SD] age, 56.5 [13.5] years; 1199 [66.0%] men), 1760 (96.9%) completed the trial. In these patients, the 28-day mortality rate was significantly different between the placebo group and the XBJ group (230 of 882 patients [26.1%] vs 165 of 878 patients [18.8%], respectively; P < .001). The absolute risk difference was 7.3 (95% CI, 3.4-11.2) percentage points. The incidence of adverse events was 222 of 878 patients (25.3%) in the placebo group and 200 of 872 patients (22.9%) in the XBJ group.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial among patients with sepsis, the administration of XBJ reduced 28-day mortality compared with placebo.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03238742.
参考来源
- Liu S, Yao C, Xie J, et al. Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial. JAMA Intern Med. 2023. PMID: 37126332. doi:10.1001/jamainternmed.2023.0780
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。